Navigation Links
Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
Date:2/2/2009

ROCKVILLE, Md., Feb. 2 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today that Richard Garr, CEO and President, will present at the 11th Annual BIO CEO & Investor Conference to be held on February 9-10, 2009, at the Waldorf=Astoria Hotel, New York City.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO)

Neuralstem's presentation is scheduled for Monday, February 9, 2009 at 10:00 a.m. Eastern Time.

The presentation will be webcast live and will be available on the Investor Relations section of Neuralstem's website at www.neuralstem.com. For those who are not available to listen to the live broadcast, the call will be archived.

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS). The Company filed an IND (Investigational New Drug) application with the FDA for ALS clinical trials in December, 2008, and has entered into a collaborative agreement with Albert-Ludwigs-University, in Freiburg, Germany, to develop clinical trials for Huntington's disease.

In pre-clinical work, the company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis i
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
2. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
3. Neuralstem Reports Second Quarter Financial Results and Highlights
4. Neuralstem Fills Key Product Development Position
5. Neuralstem Responds to New StemCells, Inc. Lawsuit
6. Neuralstem Sues StemCells, Inc. Over New Patent
7. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
8. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
9. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
10. Neuralstem Shares Accepted for Trading on Amex(R)
11. The EntreTech Forum Presents... Greening Of America - The Conversion of Bio-Agriculture, Bio-Energy, and Bio-Products to Eco-Sustainable Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... and VANCOUVER , March 31, 2015 ... EPI) announced today that it has filed with the ... Investigation New Drug ("IND") application related to the Company,s ... Approval of the IND application is required in order ... the US.  The IND application is ...
(Date:3/31/2015)... , March 31, 2015  Bayer HealthCare (Bayer) ... of Massachusetts Institute of Technology (MIT) and Harvard ... The goal of this new part of the ... to help create new cardiovascular therapies. ... the Broad Institute to the area of cardiovascular ...
(Date:3/31/2015)... 31, 2015 This June 13th, a ... top U.S and International Medical Schools will come together ... on the application of stem cell therapy in treatments ... organized and funded by the Ocular Research Symposia ... been convening intimate meetings of top experts in the ...
(Date:3/30/2015)... PMG Research, Benchmark Research, and Miami ... of VaxCorps, a network of highly experienced, geographically ... of vaccine trials in healthy adult, elderly, and ... conducted over 500 phase I-III vaccine clinical trials, ... as well as a vast array of other ...
Breaking Biology Technology:ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 2ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 3ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 4Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 2Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 3Sight Restoration Through Stem Cell Therapy - Subject of June Symposium of Experts 2PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2
... Readies R & D facilities for Ap3ana, CTI,s ... Cell Therapeutics, Inc. (CTI),(Nasdaq: CTIC ) announced ... President and COO of a Tyr Pharma and ... the Novartis Research,Foundation, has been named President of ...
... BioPharma,Corp. (TSX; FSE: HBP) today announced that it has ... 6,800,000 units at $1.68 per,unit, for gross proceeds totaling ... and one-half of one common share,purchase warrant, with each ... subject to adjustment, one common share at a price,of ...
... Investors, WILMINGTON, Del., Oct. 2 Speaking ... General Manager John Ranieri,said the company,s plans to ... on track and making significant technical progress toward ... feedstocks,economically into biofuels., "Biobutanol and cellulosic ethanol ...
Cached Biology Technology:Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4Helix Biopharma Closes $11.4 Million Private Placement 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
(Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
(Date:3/2/2015)... Lithuania , March 2, 2015   Neurotechnology ... technologies, today introduced the SentiGaze Software Development Kit ... to create applications that use off-the-shelf webcams to track ... user gazes at a monitor. Heatmaps can be used ... the effectiveness of online advertising. The SDK can also ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... obesity increasing, school administrators and public health officials are ... a study published in the November/December 2008 issue of ... researchers found that reduction or elimination of SSB from ... adolescents. Working with four schools in Maine ...
... to be averted, atmospheric carbon dioxide (CO2) must be reduced below ... in Open Atmospheric Science Journal by a ... and France. The authors, who include two Yale ... which civilization developed, an optimum CO2 level would be less than ...
... Ph.D., of the New York City Department of Health and ... be one of our body,s main protections against damage from ... of Low Radiation , Hayes explains that calcitriol, the active ... and could be used as a safe protective agent before ...
Cached Biology News:Revised theory suggests carbon dioxide levels already in danger zone 2Could vitamin D save us from radiation? 2